Thursday, February 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

NextBio Awarded $26M for Broad-Spectrum Influenza Phase 2

by Global Biodefense Staff
September 27, 2012

The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness & Response (ASPR) this week awarded $26,504,502.00 to NextBio, Incorporated, for advancement of a broad-spectrum antiviral therapeutic for treatment of Influenza A & B.

The major goal of the contract is to successfully complete a Phase 2B clinical trial which will advance candidate DAS181, an inhaled recombinant fusion protein, towards Federal Drug Administration NDA filing and approval.

DAS181 is a broad spectrum drug candidate for treatment and prevention of Influenza-Like Illness (ILI) caused by any strain of influenza and parainfluenza viruses. Unlike neuraminidase inhibitors, as well as vaccines which target the influenza virus, DAS181 works by inactivating the human receptors for these viruses. This mechanism of action makes DAS181 less likely to cause drug resistance compared with currently-available antiviral drugs.

The award is a Cost Plus Fixed Fee (CPFF) type Research and Development contract under the procedures of a Broad Agency Announcement (BAA). Further details are available under Solicitation Number: BAA-11-100-SOL-00021.

NextBio is headquartered in Santa Clara, CA.

Tags: AntiviralsASPRAwardsHHSInfluenza

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC